Renal Cancer Vaccine, IMA901, Granted Orphan Drug Designation
immatics biotechnologies GmbH announced that IMA901 has been granted orphan drug designation from the FDA for the treatment of renal cell carcinoma (RCC) in HLA-A*02 positive patients.
IMA901 is a rationally designed cancer vaccine comprising 10 different tumor-associated peptides (TUMAPs) that are found to be highly over-expressed in the majority of patients suffering from RCC. IMA901 is a peptide-based vaccine.
For more information visit www.immatics.com.